SynthesisNeurosurgical review2025
Towards molecular-guided epilepsy surgery: a systematic review and meta-analysis of microRNAs and other regulatory non-coding RNAs.
Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-coding RNAs (ncRNAs)—including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and related species—have emerged as promising molecular biomarkers in epilepsy, but their diagnostic, prognostic, and therapeutic roles remain incompletely defined. We conducted a PRISMA 2020–compliant systematic review and meta-analysis (PROSPERO-registered). PubMed, Scopus, and Web of Science (2000–2025) were searched for studies evaluating ncRNA expression or clinical relevance in human epilepsy or validated animal models that reported diagnostic, prognostic, or treatment-response outcomes. Study quality was assessed with the Newcastle–Ottawa Scale, and pooled diagnostic estimates were generated when data allowed. Ninety-four studies met inclusion criteria: 79 investigated miRNAs, 10 lncRNAs, and several assessed piRNAs or circRNAs. The pooled area under the curve (AUC) for miRNA-based diagnostic models was 0.85, with mean sensitivity 76.5% and specificity 78.1%. lncRNAs showed a comparable mean AUC of 0.87, although based on fewer datasets. Recurrent biomarkers—particularly miR-134, miR-146a, and the lncRNA MALAT1—were consistently linked to drug-resistant epilepsy, higher seizure frequency, and poorer clinical control. Mechanistic analyses indicated that these ncRNAs regulate neuroinflammatory signaling, synaptic remodeling, and ion-channel–related pathways that are central to epileptogenesis. Overall, most studies were of moderate-to-high methodological quality. ncRNAs, especially circulating miRNAs, show strong potential as minimally invasive diagnostic and prognostic biomarkers in epilepsy and could support molecularly guided patient stratification and treatment monitoring. Future work should prioritize large prospective cohorts, assay standardization, and cross-platform validation to enable clinical translation.
Indexed as
Identifiers
41366125What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.